Lung Cancer section

Lung Cancer News & Features

Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes

Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes

E-cigarettes used with nicotine-based liquid have the same potential to produce cancer-causing DNA damage as unfiltered regular cigarettes.

Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC

Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC

Phase 3 clinical trial results show fewer adverse effects and longer survival with alectinib compared with crizotinib in patients with treatment-naïve ALK-positive NSCLC.

Improved Outcomes in Lung Cancer With Hyperfractionated Chemoradiation Therapy

Improved Outcomes in Lung Cancer With Hyperfractionated Chemoradiation Therapy

Twice daily radiation therapy with chemotherapy may improve survival times in patients with some advanced head and neck cancers, a new study confirms.

Filtered Cigarettes May Increase Rates of Lung Adenocarcinoma

Filtered Cigarettes May Increase Rates of Lung Adenocarcinoma

The design of cigarette filters with ventilation is associated with rising adenocarcinoma rates, research indicates.

No Improvement in KRAS-Mutation Lung Cancer With MEK Inhibitor Plus Chemotherapy

No Improvement in KRAS-Mutation Lung Cancer With MEK Inhibitor Plus Chemotherapy

A combination treatment of mitogen-activated protein kinase MEK inhibitor and chemotherapy did not improve progression-free survival in patients with advanced lung cancer caused by a KRAS gene mutation.

Influenza Vaccination Increases Toxicity in PD-1/PD-L1 Immunotherapy Blockade for Lung Cancer

Influenza Vaccination Increases Toxicity in PD-1/PD-L1 Immunotherapy Blockade for Lung Cancer

Seasonal influenza vaccination was associated with increased rates of immunologic toxicity in patients with lung cancer receiving PD-1/PD-L1 immunotherapy blockade.

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.

Pembrolizumab May Help Combat Mesothelioma

Pembrolizumab May Help Combat Mesothelioma

Checkpoint inhibitor pembrolizumab appears well-tolerated with antitumor activity in patients with malignant pleural mesothelioma.

Radiation Therapy for Locally Advanced NSCLC Linked to Cardiac Events

Radiation Therapy for Locally Advanced NSCLC Linked to Cardiac Events

Risk for cardiac events linked to RT for locally advanced NSCLC, especially in patients with a history of cardiac disease or receiving higher RT doses.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs